55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response…
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response…
REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the…
REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the…
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology…
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology…
Tilray Continues to Lead Cannabis Market Share Across Canada LEAMINGTON, Ontario, July 27, 2023 (GLOBE…
Tilray Continues to Lead Cannabis Market Share Across Canada LEAMINGTON, Ontario, July 27, 2023 (GLOBE…
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is…
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is…
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00…
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00…
Anaphylm 12mg Exceeds Lower Bracket at All Expected Pivotal Targets Anaphylm 12mg Exceeds Lower Bracket…
Anaphylm 12mg Exceeds Lower Bracket at All Expected Pivotal Targets Anaphylm 12mg Exceeds Lower Bracket…
Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is…
Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is…
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…